Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population

详细信息    查看全文

• 作者：Pusen Wang ; Weiyong Song ; Hao Li ; Cunguang Wang ; Baojie Shi ; Wenzhi Guo…
• 关键词：SMO polymorphism ; Hepatocellular carcinoma ; Recurrence ; Orthotopic liver transplantation ; Prognosis
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：36
• 期：10
• 页码：7807-7815
• 全文大小：585 KB
• 参考文献：1.El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-6. doi:10.-053/?j.?gastro.-007.-4.-61 .CrossRef PubMed
  2.Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(4):187-6. doi:10.-007/?s00432-003-0511-1 .CrossRef PubMed
  3.Lee KK, Kim DG, Moon IS, Lee MD, Park JH. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol. 2010;101(1):47-3. doi:10.-002/?jso.-1415 .CrossRef PubMed
  4.Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143(2):182-. doi:10.-001/?archsurg.-007.-9 . discussion 8.CrossRef PubMed
  5.Chen J, Xu X, Wu J, Ling Q, Wang K, Wang W, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS One. 2014;9(3):e93128. doi:10.-371/?journal.?pone.-093128 .PubMed Central CrossRef PubMed
  6.Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15(4):1001-. doi:10.-245/?s10434-007-9559-5 .PubMed Central CrossRef PubMed
  7.Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-03. doi:10.-053/?jhep.-001.-4563 .CrossRef PubMed
  8.Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, et al. Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation. Hepatology. 2014. doi:10.-002/?hep.-7358 .PubMed
  9.Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285-. doi:10.-038/?ng.-526 .PubMed Central CrossRef PubMed
  10.Wang C, Wu H, Katritch V, Han GW, Huang XP, Liu W, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature. 2013;497(7449):338-3. doi:10.-038/?nature12167 .PubMed Central CrossRef PubMed
  11.Che L, Yuan YH, Jia J, Ren J. Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu. 2012;24(4):323-1. doi:10.-978/?j.?issn.-000-9604.-012.-0.-0 .CrossRef PubMed
  12.Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis. 2006;27(7):1334-0. doi:10.-093/?carcin/?bgi378 .CrossRef PubMed
  13.Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res. 2007;67(8):3583-3. doi:10.-158/-008-5472.?CAN-06-3040 .CrossRef PubMed
  14.Jeng KS, Sheen IS, Jeng WJ, Lin CC, Lin CK, Su JC, et al. High expression of patched homolog-1 messenger RNA and glioma-associated oncogene-1 messenger RNA of sonic hedgehog signaling pathway indicates a risk of postresection recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2013;20(2):464-3. doi:10.-245/?s10434-012-2593-y .CrossRef PubMed
  15.Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One. 2011;6(9):e23943. doi:10.-371/?journal.?pone.-023943 .PubMed Central CrossRef PubMed
  16.Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, et al. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res : Off J Am Assoc Cancer Res. 2012;18(5):1291-02. doi:10.-158/-078-0432.?CCR-11-0950 .CrossRef
  17.Mao J, Fan PH, Ma W, Zhang QQ, Wang B, Fan SJ, et al. Down-regulation of Smoothened gene expression inhibits proliferation of breast cancer stem cells. Zhonghua Bing Li Xue Za Zhi Chin J Pathol. 2013;42(4):262-. doi:10.-760/?cma.?j.?issn.-529-5807.-013.-4.-11 .
  18.Ruat M, Hoch L, Faure H, Rognan D. Targeting of Smoothened for therapeutic gain. Trends Pharmacol Sci. 2014;35(5):237-6. doi:10.-016/?j.?tips.-014.-3.-02 .CrossRef PubMed
  19.Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant : Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(4):783-0. doi:10.-111/?j.-600-6143.-006.-1242.?x .CrossRef
  20.Segev DL, Maley WR, Sim
• 作者单位：Pusen Wang (1)
  Weiyong Song (2)
  Hao Li (1)
  Cunguang Wang (1)
  Baojie Shi (1)
  Wenzhi Guo (3)
  Lin Zhong (1)
  
  1. Department of General Surgery, Affiliated First People’s Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China
  2. Department of General Surgery, The First People’s Hospital of Yongkang City, Yongkang City, Zhejiang Province, 321300, China
  3. Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation, The first Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Hepatocellular carcinoma (HCC) recurrence after orthotopic liver transplantation (OLT) is potential cause for the poor outcome. Smoothened (SMO) gene has been considered associating with HCC and HCC recurrence, but its association with HCC recurrence after OLT is not clear yet. In this study, we aim at evaluating the association between donor and recipient SMO gene polymorphisms and HCC recurrence after OLT. A total of 76 patients with HCC who had undergone OLT from July 2007 to August 2012 were included. A single nucleotide polymorphism (SNP), SMO rs3824, located at the 3′UTR region, was genotyped and analyzed in both donor and recipient. We demonstrated that recipient rs3824 polymorphism was significantly associated with HCC recurrence following OLT. In multivariate logistic regression analysis, TNM stage (p--.001), recipient SMO rs3824 genotype (CG vs. CC/GG p--.001), and histologic grade (p--.019) were identified as independent risk factors of HCC recurrence. Recurrence-free survival (RFS) and overall survival (OS) were significantly higher in the recipient CC/GG group than in the CG group (p--.003 and p--.011, respectively). Cox proportional hazards modeling revealed that TNM stage, recipient SMO rs3824 genotype, pre-OLT serum AFP level, and histologic grade were independent factors (p-lt;-.05) for patients-clinical outcomes. In conclusion, recipient SMO rs3824 polymorphism is associated with an increased risk of HCC recurrence following OLT and has a potential clinical value for the prognosis of HCC patients treated with OLT. Keywords SMO polymorphism Hepatocellular carcinoma Recurrence Orthotopic liver transplantation Prognosis